|
May 9
|
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 9
|
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
|
|
Apr 4
|
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
|
|
Mar 19
|
Tempest Reports Year End 2023 Financial Results and Provides Business Update
|
|
Mar 12
|
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
|
|
Mar 5
|
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
|
|
Dec 1
|
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 20
|
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
|
|
Sep 19
|
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
|